A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene and pembrolizumab after surgery can help prevent the cancer from coming back in people with non-small cell lung cancer (NSCLC) whose tumors did not respond completely to treatment before surgery (neoadjuvant treatment).

Trial Details

NCT ID
NCT06623422
Phase
PHASE3
Sponsor
Merck Sharp & Dohme LLC
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Pembrolizumab
  • Cisplatin
  • Carboplatin
  • Pemetrexed
  • Gemcitabine
  • Paclitaxel
Locations (sample)
  • Gilbert, Arizona, United States|33.35283,-111.78903
  • Tucson, Arizona, United States|32.22174,-110.92648
  • Fullerton, California, United States|33.87029,-117.92534
  • Long Beach, California, United States|33.76696,-118.18923
  • Los Angeles, California, United States|34.05223,-118.24368

Key Eligibility Criteria

  • The main inclusion criteria include but are not limited to the following:
  • Has histologically/cytologically confirmed diagnosis of previously untreated and pathologically confirmed resectable clinical Stage II, IIIA, or II…
  • Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days before the first dose of study intervention
  • Participants who have not achieved a pathological complete response (pCR) following completion of neoadjuvant chemotherapy and pembrolizumab follow…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →